No profile data available.
Bausch Health Companies Inc. (BHC) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Laval, Canada, with about 20,300 full-time employees.
It reported revenue of $10.27 billion for fiscal year 2025, up 6.7% from fiscal year 2024, and net income of $157.00 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $2.52 billion, up 11.7% from a year before. Its largest business segment, Bausch + Lomb, brought in 50% of segment revenue in fiscal year 2025; United States was the largest region with 60%. Its market capitalization was $2.26 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.
Bausch Health Companies reported $10.27 billion in revenue for fiscal year 2025, up 6.7% from $9.63 billion in fiscal year 2024. In Q1 2026 revenue was $2.52 billion.
Bausch + Lomb, with $5.10 billion or 50% of segment revenue in fiscal year 2025. Next: Salix (25%) and International (11%).
United States: 60% of revenue by region in fiscal year 2025, followed by Other (11%).
$2.26 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Adma Biologics, Inc. (ADMA), Nurix Therapeutics, Inc. (NRIX), Prestige Consumer Healthcare Inc. (PBH), Perrigo Company plc (PRGO).